Precision Oncology in Breast Cancer Surgery

Outcomes for patients with breast cancer have improved over time due to increased screening and the availability of more effective therapies. It is important to recognize that breast cancer is a heterogeneous disease that requires treatment based on molecular characteristics. Early endpoints such as...

Full description

Saved in:
Bibliographic Details
Published inSurgical oncology clinics of North America Vol. 33; no. 2; p. 293
Main Authors Abbasi, Ali Benjamin, Wu, Vincent, Lang, Julie E, Esserman, Laura J
Format Journal Article
LanguageEnglish
Published United States 01.04.2024
Subjects
Breast Neoplasms - pathology
Female
Humans
Medical Oncology
Precision Medicine
Risk Factors
Biomarker
Precision screening
Precision medicine
Personalized medicine
Precision oncology
Breast surgery
Online AccessGet more information

Cover

More Information
Summary:Outcomes for patients with breast cancer have improved over time due to increased screening and the availability of more effective therapies. It is important to recognize that breast cancer is a heterogeneous disease that requires treatment based on molecular characteristics. Early endpoints such as pathologic complete response correlate with event-free survival, allowing the opportunity to consider de-escalation of certain cancer treatments to avoid overtreatment. This article discusses clinical trials of tailoring treatment (eg, I-SPY2) and screening (eg, WISDOM) to individual patients based on their unique risk features.
ISSN:1558-5042
DOI:10.1016/j.soc.2023.12.011